Zuellig Pharma在泰国推出礼来公司的Mounjaro®（tirzepatide）用于治疗肥胖症和糖尿病
The launch of Mounjaro® in Thailand provides a much-needed advanced therapeutic option for the growing number of patients suffering from obesity and type 2 diabetes in the country. This aligns with regional efforts to combat the rising prevalence of these metabolic diseases, offering improved patient outcomes and quality of life through access to innovative treatments.
Launched Mounjaro® (tirzepatide) for obesity and diabetes.
Partnership with Eli Lilly for market introduction in Thailand.
Provides advanced treatment for chronic metabolic diseases.
This product launch in Thailand addresses the significant and growing burden of obesity and diabetes in the APAC region, offering a new treatment option for patients.
Partnership with Eli Lilly for market introduction in Thailand.
Provides advanced treatment for chronic metabolic diseases.
登录后可保存信号笔记。
登录